# MAMDC2

## Overview
MAMDC2 is a gene that encodes the MAM domain containing 2 protein, which is a putative secretory protein involved in cell adhesion and signaling. The protein is characterized by the presence of four consecutive MAM domains, which are conserved protein domains found in various cell surface proteins. These domains are implicated in mediating cell growth inhibition and are involved in interactions with the MAPK signaling pathway, suggesting a regulatory role in cell proliferation and survival (Lee2020MAM). MAMDC2 is secreted into the extracellular space, where it may participate in extracellular interactions, potentially influencing cell signaling and communication (Lee2020MAM). The gene and its encoded protein have been studied for their roles in various cancers, where they may serve as potential biomarkers and therapeutic targets due to their involvement in tumor-suppressive activities and interactions with the tumor microenvironment (Cheng2023Identification; Xie2023Identification).

## Structure
The MAMDC2 protein is a putative secretory protein consisting of 686 amino acids. It features a short N-terminal signal sequence, which is indicative of its role in secretion, and four consecutive MAM domains, labeled D1, D2, D3, and D4 from the N-terminus (Lee2020MAM). The MAM domain is a conserved protein domain found in various cell surface proteins and is involved in cell adhesion and signaling (Lee2020MAM). MAMDC2 is predicted to be a secretory protein due to the presence of this signal sequence and the absence of transmembrane domains, which was confirmed by experiments showing its secretion into the extracellular space (Lee2020MAM).

The protein is N-glycosylated, a common post-translational modification that can affect protein folding, stability, and interactions (Lee2020MAM). Intracellular localization studies have shown that MAMDC2 co-localizes with the endoplasmic reticulum, suggesting its synthesis in the ER and subsequent release via a secretory pathway (Lee2020MAM). The second MAM domain (D2) is particularly significant, as it may play a crucial role in mediating cell growth inhibition (Lee2020MAM).

## Clinical Significance
MAMDC2 has been implicated in several cancers due to its altered expression levels and potential as a biomarker. In gastric cancer, MAMDC2 is significantly correlated with immune cell infiltration characteristics, showing positive correlations with T cell CD4+ memory resting and mast cell activation, while negatively correlating with macrophage M0 and T cell CD4+ memory activated cells. These interactions suggest a complex role in the tumor microenvironment, influencing prognosis and survival outcomes (Xie2023Identification). In breast cancer, MAMDC2 is down-regulated in tumor tissues and is associated with improved survival rates, particularly in estrogen receptor-positive cases. Its overexpression inhibits cell proliferation in certain breast cancer cell lines, indicating a tumor-suppressive function (Lee2020MAM). In bladder cancer, MAMDC2 is identified as a potential biomarker due to its differential expression and methylation patterns, which may contribute to cancer cell proliferation and survival (Cheng2023Identification). In chronic myeloid leukemia, MAMDC2 is overexpressed in leukemic stem cells compared to normal hematopoietic stem cells, suggesting a role in the disease's pathogenesis (Avilés‐Vázquez2017Global). These findings highlight MAMDC2's clinical significance across various cancer types.

## Interactions
MAMDC2 is implicated in interactions with components of the MAPK signaling pathway, particularly affecting the phosphorylation levels of RAF1 and ERK1/2. This suggests that MAMDC2 may regulate cell growth by modulating the RAF-ERK pathway, which is a critical signaling cascade involved in cell proliferation and survival. The study found that MAMDC2 overexpression inhibited cell proliferation in certain breast cancer cell lines, such as T-47D and MCF-7, but not in MDA-MB-231 cells, indicating a context-dependent interaction with the MAPK pathway (Lee2020MAM).

MAMDC2 is also predicted to be a secretory protein, and experiments confirmed its secretion into the extracellular space. This suggests that MAMDC2 may participate in extracellular interactions, potentially influencing cell signaling and communication. The protein's co-localization with the endoplasmic reticulum supports its synthesis and release via a secretory pathway, although specific interacting partners in the extracellular environment have not been identified due to the lack of a specific antibody for detection (Lee2020MAM).

These interactions highlight MAMDC2's potential role as an extracellular regulator of cell proliferation and its involvement in signaling pathways that may contribute to its tumor-suppressive activity in breast cancer.


## References


[1. (Lee2020MAM) Hyeonhee Lee, Bum‐Chan Park, Jong Soon Kang, Yeongmi Cheon, Soojin Lee, and Pil Jae Maeng. Mam domain containing 2 is a potential breast cancer biomarker that exhibits tumour‐suppressive activity. Cell Proliferation, July 2020. URL: http://dx.doi.org/10.1111/cpr.12883, doi:10.1111/cpr.12883. This article has 18 citations and is from a peer-reviewed journal.](https://doi.org/10.1111/cpr.12883)

[2. (Cheng2023Identification) Hongxia Cheng, Yuhua Liu, and Gang Chen. Identification of potential dna methylation biomarkers related to diagnosis in patients with bladder cancer through integrated bioinformatic analysis. BMC Urology, August 2023. URL: http://dx.doi.org/10.1186/s12894-023-01307-5, doi:10.1186/s12894-023-01307-5. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12894-023-01307-5)

[3. (Xie2023Identification) Rongjun Xie, Longfei Liu, Xianzhou Lu, Chengjian He, and Guoxin Li. Identification of the diagnostic genes and immune cell infiltration characteristics of gastric cancer using bioinformatics analysis and machine learning. Frontiers in Genetics, January 2023. URL: http://dx.doi.org/10.3389/fgene.2022.1067524, doi:10.3389/fgene.2022.1067524. This article has 6 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fgene.2022.1067524)

[4. (Avilés‐Vázquez2017Global) Sócrates Avilés‐Vázquez, Antonieta Chávez‐González, Alfredo Hidalgo‐Miranda, Dafne Moreno‐Lorenzana, Lourdes Arriaga‐Pizano, Miguel Á. Sandoval‐Esquivel, Manuel Ayala‐Sánchez, Rafael Aguilar, Luis Alfaro‐Ruiz, and Hector Mayani. Global gene expression profiles of hematopoietic stem and progenitor cells from patients with chronic myeloid leukemia: the effect of in vitro culture with or without imatinib. Cancer Medicine, 6(12):2942–2956, October 2017. URL: http://dx.doi.org/10.1002/cam4.1187, doi:10.1002/cam4.1187. This article has 17 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/cam4.1187)